ES2169251T3 - Peptidos de somatostatina. - Google Patents

Peptidos de somatostatina.

Info

Publication number
ES2169251T3
ES2169251T3 ES96924811T ES96924811T ES2169251T3 ES 2169251 T3 ES2169251 T3 ES 2169251T3 ES 96924811 T ES96924811 T ES 96924811T ES 96924811 T ES96924811 T ES 96924811T ES 2169251 T3 ES2169251 T3 ES 2169251T3
Authority
ES
Spain
Prior art keywords
sub
ala
lys
amino acid
waste
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96924811T
Other languages
English (en)
Spanish (es)
Inventor
Rainer Albert
Wilfried Bauer
Christian Bruns
Nagarajan Chandramouli
Ian Lewis
Gisbert Weckbecker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26307298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2169251(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9513224.7A external-priority patent/GB9513224D0/en
Priority claimed from GBGB9600429.6A external-priority patent/GB9600429D0/en
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2169251T3 publication Critical patent/ES2169251T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/655Somatostatins
    • C07K14/6555Somatostatins at least 1 amino acid in D-form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/655Somatostatins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/31Somatostatins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
ES96924811T 1995-06-29 1996-06-28 Peptidos de somatostatina. Expired - Lifetime ES2169251T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9513224.7A GB9513224D0 (en) 1995-06-29 1995-06-29 Organic compounds
GBGB9600429.6A GB9600429D0 (en) 1996-01-10 1996-01-10 Organic compounds

Publications (1)

Publication Number Publication Date
ES2169251T3 true ES2169251T3 (es) 2002-07-01

Family

ID=26307298

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96924811T Expired - Lifetime ES2169251T3 (es) 1995-06-29 1996-06-28 Peptidos de somatostatina.

Country Status (24)

Country Link
US (1) US6225284B1 (pt)
EP (1) EP0835263B9 (pt)
JP (2) JP3445796B2 (pt)
KR (1) KR100454664B1 (pt)
CN (1) CN1156492C (pt)
AT (1) ATE210152T1 (pt)
AU (1) AU714447B2 (pt)
BR (1) BR9609335B8 (pt)
CA (1) CA2222524C (pt)
CZ (1) CZ297381B6 (pt)
DE (1) DE69617687T2 (pt)
DK (1) DK0835263T3 (pt)
ES (1) ES2169251T3 (pt)
HU (1) HU228984B1 (pt)
IL (1) IL122243A (pt)
MY (1) MY147327A (pt)
NO (1) NO317867B1 (pt)
NZ (1) NZ313147A (pt)
PL (1) PL184947B1 (pt)
PT (1) PT835263E (pt)
SK (1) SK284087B6 (pt)
TR (1) TR199701718T1 (pt)
TW (1) TW491854B (pt)
WO (1) WO1997001579A2 (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238340B1 (en) * 1991-11-27 2007-07-03 Cis Bio International Monoamine, diamide, thiol-containing metal chelating agents
JPH10251296A (ja) * 1997-03-06 1998-09-22 American Cyanamid Co ソマトスタチン拮抗薬として有用なペプチド
WO1998051331A1 (en) 1997-05-13 1998-11-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) Somatostatin and somatostatin agonists for decreasing body weight
US7026289B2 (en) 1997-05-13 2006-04-11 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Method and compositions for treating hyperlipidemia and other conditions
US6004928A (en) * 1997-05-13 1999-12-21 Biomeasure, Incorporated Method of treating hyperlipidemia
US5968903A (en) * 1998-05-07 1999-10-19 Biomeasure, Incorporated Inhibition of H. pylori proliferation
SE9802080D0 (sv) * 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6358491B1 (en) 1999-08-27 2002-03-19 Berlex Laboratories, Inc. Somatostatin analogs
EP1233776A4 (en) * 1999-11-29 2003-05-07 Smithkline Beecham Corp CYCLIC UROTENSIN II ANALOGS
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US7122172B1 (en) 2000-03-08 2006-10-17 Gerhart Graupner Methods and compositions for targeted drug delivery
US7906103B2 (en) 2000-03-08 2011-03-15 Gerhard Graupner Methods and compositions for targeted drug delivery
JP3996897B2 (ja) 2001-06-08 2007-10-24 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス ソマトスタチン−ドーパミンキメラ類似体
US7189856B2 (en) * 2001-12-28 2007-03-13 Gideon Shapiro Non-peptide somatostatin receptor ligands
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
DE60335608D1 (de) * 2002-02-27 2011-02-17 Pharmain Corp Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US7122622B2 (en) 2002-04-16 2006-10-17 Biosynthema Inc. Peptide compounds having improved binding affinity to somatostatin receptors
EP1358890A1 (en) 2002-05-03 2003-11-05 BioSynthema, Inc Benzothienyl analogue of somatostatine, selective for certain somatostatin receptors
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
DE60336550D1 (de) * 2002-05-20 2011-05-12 Bristol Myers Squibb Co Inhibitoren des hepatitis-c-virus
JP4312711B2 (ja) 2002-05-20 2009-08-12 ブリストル−マイヤーズ スクイブ カンパニー ヘテロ環式スルホンアミドc型肝炎ウイルス阻害剤
AU2003301959A1 (en) 2002-05-20 2004-06-03 Bristol-Myers Squibb Company Substituted cycloalkyl p1' hepatitis c virus inhibitors
BR0316523A (pt) * 2002-11-25 2005-10-18 Attenuon Llc Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente
GB0229020D0 (en) * 2002-12-12 2003-01-15 Novartis Ag Organic compounds
KR101018491B1 (ko) * 2002-12-12 2011-03-03 노파르티스 아게 4-히드록시-프롤린 하부구조를 포함하는 펩티드의 합성 방법
GB0300095D0 (en) * 2003-01-03 2003-02-05 Novartis Ag Organic compounds
AU2004232314B2 (en) 2003-04-22 2007-11-22 Ipsen Pharma S.A.S. Peptide vectors
AR044852A1 (es) * 2003-06-24 2005-10-05 Novartis Ag Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
MXPA06003141A (es) 2003-09-22 2006-06-05 Boehringer Ingelheim Int Peptidos macrociclicos activos contra el virus de la hepatitis c.
EP1522311A1 (fr) * 2003-10-10 2005-04-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation de la somatostine ou d'un de ses analogues pour préparer un médicament destiné à réguler la réserve folliculaire ovarienne chez la femme non ménopausée
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MY158342A (en) 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
GB0326602D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP4682155B2 (ja) 2004-01-21 2011-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング C型肝炎ウイルスに対して活性な大環状ペプチド
GB0428151D0 (en) 2004-12-22 2005-01-26 Novartis Ag Organic compounds
EP1717247A1 (en) * 2005-04-28 2006-11-02 Schering AG Cyclic peptides binding to the somatostatin receptor
WO2006114324A1 (en) * 2005-04-28 2006-11-02 Schering Ag Compounds comprising cyclized somatostatin receptor binding peptides
EP1941902A1 (en) * 2007-01-02 2008-07-09 Novartis AG Use of Somatostatin analogs in cluster headache
KR20100038417A (ko) * 2007-06-29 2010-04-14 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
JP5465666B2 (ja) * 2007-06-29 2014-04-09 ギリアード サイエンシーズ, インコーポレイテッド 抗ウイルス化合物
RU2523416C2 (ru) 2007-11-28 2014-07-20 Новартис Аг Применение аналогов соматостатина при менингиоме
CN101883785B (zh) * 2007-12-03 2014-01-15 意大利法尔马科有限公司 新的非选择性生长抑素类似物
EP2067786A1 (en) 2007-12-07 2009-06-10 ITALFARMACO S.p.A. Novel non selective analogs of somatostatin
EP3590956A1 (en) 2008-06-12 2020-01-08 Ipsen Bioinnovation Limited Suppression of neuroendocrine diseases
JP5799397B2 (ja) 2008-06-12 2015-10-28 イプセン・バイオイノベーション・リミテッドIpsen Bioinnovation Limited 癌の抑制
DK2310042T3 (da) 2008-07-08 2013-03-04 Novartis Ag Anvendelse af pasireotid til behandling af endogen hyperinsulinæmisk hypoglykæmi
EP2213307A1 (en) 2009-02-03 2010-08-04 Novartis AG Injectable depot formulations
EP2172189A1 (en) 2008-10-01 2010-04-07 Novartis AG Pharmaceutical Compositions
EP2168983A1 (fr) 2008-09-30 2010-03-31 Ipsen Pharma Nouveaux composés octapeptidiques et leur utilisation thérapeutique
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
UY32325A (es) * 2008-12-19 2010-07-30 Gilead Sciences Inc Inhibidores de ns3 proteasa del vhc
EP2380596A1 (en) * 2010-04-20 2011-10-26 Technische Universität München Cyclopentapeptide derivatives and uses thereof
EP3233899B1 (en) 2014-12-19 2020-06-24 Auro Peptides LTD A process for the preparation of pasireotide
CN106432429A (zh) * 2016-10-24 2017-02-22 合肥国肽生物科技有限公司 一种帕西瑞肽的合成方法
RS64815B1 (sr) 2017-01-12 2023-12-29 Radiomedix Inc Lečenje ćelija kancera koje prekomerno eksprimiraju receptore za somatostatin primenom derivata oktreotida heliranih sa radioizotopima
US10596278B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3863008A (en) * 1973-06-11 1975-01-28 American Home Prod Somatostatin as stimulant of luteinizing hormone secretion
NZ195303A (en) * 1979-10-31 1984-10-19 Merck & Co Inc Cyclic hexapeptide somatostatin analogues,and pharmaceutical compositions
US4292972A (en) * 1980-07-09 1981-10-06 E. R. Squibb & Sons, Inc. Lyophilized hydrocolloio foam
US4505897A (en) * 1983-04-18 1985-03-19 The Administrators Of The Tulane Educational Fund Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith
US4612366A (en) 1985-06-17 1986-09-16 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
CA2012115C (en) * 1989-03-15 2001-07-03 Biomeasure, Inc. Iodinated somatostatins
CA2053250A1 (en) 1989-04-26 1990-10-27 David H. Coy Linear somatostatin analogs
US5716596A (en) * 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
CA2167281C (en) * 1993-07-15 2001-09-04 Richard T. Dean Radiolabeled somatostatin-derived peptides for imaging and therapeutic uses

Also Published As

Publication number Publication date
WO1997001579A3 (en) 1997-02-27
HU228984B1 (en) 2013-07-29
BR9609335B8 (pt) 2014-10-07
BR9609335B1 (pt) 2009-08-11
CZ297381B6 (cs) 2006-11-15
JPH11506108A (ja) 1999-06-02
JP3445796B2 (ja) 2003-09-08
CA2222524A1 (en) 1997-01-16
JP2003104998A (ja) 2003-04-09
IL122243A (en) 2005-09-25
SK177097A3 (en) 1998-08-05
NZ313147A (en) 1999-11-29
DE69617687D1 (de) 2002-01-17
NO317867B1 (no) 2004-12-27
WO1997001579A2 (en) 1997-01-16
NO976064L (no) 1998-02-16
US6225284B1 (en) 2001-05-01
DE69617687T2 (de) 2002-08-22
HUP9901455A2 (hu) 1999-09-28
KR19990028480A (ko) 1999-04-15
EP0835263B1 (en) 2001-12-05
KR100454664B1 (ko) 2005-09-12
SK284087B6 (sk) 2004-09-08
AU6515096A (en) 1997-01-30
CN1156492C (zh) 2004-07-07
CA2222524C (en) 2010-01-26
TW491854B (en) 2002-06-21
ATE210152T1 (de) 2001-12-15
EP0835263B9 (en) 2002-07-24
CN1189166A (zh) 1998-07-29
HUP9901455A3 (en) 2000-11-28
IL122243A0 (en) 1998-04-05
NO976064D0 (no) 1997-12-23
AU714447B2 (en) 2000-01-06
TR199701718T1 (xx) 1998-05-21
PL184947B1 (pl) 2003-01-31
MY147327A (en) 2012-11-30
PT835263E (pt) 2002-04-29
DK0835263T3 (da) 2002-04-02
EP0835263A2 (en) 1998-04-15
BR9609335A (pt) 1999-05-25
CZ419697A3 (cs) 1998-05-13
PL323943A1 (en) 1998-04-27

Similar Documents

Publication Publication Date Title
ES2169251T3 (es) Peptidos de somatostatina.
ATE245659T1 (de) Insulinabkömmlinge
ATE201696T1 (de) Zyklische peptidanaloga von somatostatin
HUP0003592A2 (hu) LH-RH peptid analógok, alkalmazásuk, és ezeket tartalmazó gyógyászati készítmények
PT883687E (pt) Receptores de quimiocinas c-c, ckr-5, cc, os seus derivados e as suas utilizacoes
NO960939D0 (no) Kininogenaseinhibitor
DE69029377D1 (de) Substituierungsanaloge von magaininpeptiden
MX9709962A (es) Peptidos de somatostatina.
ECSP961798A (es) Peptidos de somatostatina
MX9205978A (es) Nuevas proteinas inhibidoras de trombina de garrapatas.
AR247473A1 (es) Una composicion que produce una respuesta lactogenica o crecimiento en ganado bovino, excluidas todas sus aplicaciones terapeuticas

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 835263

Country of ref document: ES